MedTrace Logo

Neurofeedback in Clinical High Risk

NCT06492343 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-07-09

No results posted yet for this study

Summary

The goal of this trial is to test whether fMRI based neurofeedback from default mode network (DMN) will reduce DMN hyperconnectivity in clinical high risk individuals, which will lead to reductions in clinical symptoms and improve cognitive performance.

Conditions

  • Real Neurofeedback From DMN
  • Sham Neurofeedback From Motor Cortex

Interventions

OTHER

fMRI based neurofeedback

participants will receive neurofeedback from their brain in order to modify their own brain function

Sponsors & Collaborators

  • Boston VA Research Institute, Inc.

    lead OTHER

Principal Investigators

  • margaret niznikiewicz, phd · Boston VA Research Institute, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2028-08-31
Completion
2028-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492343 on ClinicalTrials.gov